Literature DB >> 28288708

Transformation of marginal zone lymphoma (and association with other lymphomas).

Carla Casulo1, Jonathan Friedberg2.   

Abstract

Marginal zone lymphomas (MZL) are a diverse group of indolent lymphoproliferative disorders that comprise three subtypes: nodal, splenic and mucosal associated marginal zone lymphomas (MALT). Histologic transformation (HT) to an aggressive lymphoma is a rare event that can occur in any subtype, and at lower frequency compared to other indolent non Hodgkin lymphomas (NHL) like follicular lymphoma. There are few data directly associated with risk and prognosis of transformation in MZL. However, recent advances in the understanding of molecular and genetic features of MALT have contributed to an evolving appreciation of HT in this disease. Optimal treatment of HT of MZL remains unknown. Much of the approach to managing transformed MZL is extrapolated from other indolent NHLs.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aggressive lymphoma; Marginal zone lymphoma; Non-Hodgkin lymphoma; Transformation

Mesh:

Year:  2016        PMID: 28288708     DOI: 10.1016/j.beha.2016.08.029

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  6 in total

1.  Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells.

Authors:  Christelle Vincent-Fabert; Isabelle Soubeyran; Valérie Velasco; Marie Parrens; Robin Jeannet; Emilie Lereclus; Nathalie Gachard; Jean Feuillard; Nathalie Faumont
Journal:  Cell Mol Immunol       Date:  2019-04-09       Impact factor: 11.530

Review 2.  Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature.

Authors:  Vadim Romanovich Gorodetskiy; Natalya Alexandrovna Probatova; Stefka Gospodinova Radenska-Lopovok; Natalya Valerievna Ryzhikova; Yulia Vladimirovna Sidorova; Andrey Borisovich Sudarikov
Journal:  Rheumatol Int       Date:  2019-11-09       Impact factor: 2.631

3.  First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad Kahl; Peter Wood; Tim Hawkins; David MacDonald; David Simpson; Kathryn Kolibaba; Samar Issa; Julie Chang; Judith Trotman; Doreen Hallman; Ling Chen; John M Burke
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

4.  Immunocytochemical study of canine lymphomas and its correlation with exposure to tobacco smoke.

Authors:  K C Pinello; M Santos; L Leite-Martins; J Niza-Ribeiro; A J de Matos
Journal:  Vet World       Date:  2017-11-07

5.  Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation?

Authors:  Petr Dvorak; Petr Hoffmann; Martin Simkovic; Jiri Jandura; Marketa Nova
Journal:  Arch Med Sci       Date:  2018-12-31       Impact factor: 3.318

6.  Splenic Marginal Zone Lymphoma With Histological Transformation to Hodgkin's Lymphoma.

Authors:  Sindhusha Veeraballi; Noreen Mirza; Zaineb Khawar; Hamid Shaaban
Journal:  Cureus       Date:  2022-07-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.